Primary Sclerosing Cholangitis

• Genetic predisposition and immune dysregulation: PSC demonstrates strong genetic associations, most notably with HLA-B8 and HLA-DR3 alleles, suggesting inherited susceptibility to aberrant immune responses. The concordance in monozygotic twins is incomplete (<10%), indicating polygenic inheritance with environmental modulation. The immunopathogenesis involves autoimmune attack on biliary epithelium mediated by CD4+ and CD8+ T cells. Cross-reactive immunity may play a role, where antigens from enteric bacteria (particularly from altered colonic microbiota in IBD patients) may trigger responses against biliary epithelial cell antigens through molecular mimicry. PSC sera contain multiple autoantibodies including antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), and anti-centromere antibody (ACA), though these are non-specific. The pathogenic role of autoantibodies targeting pyruvate dehydrogenase complex (antibodies similar to those in primary biliary cholangitis) and other biliary-specific autoantigens remains an area of active investigation. T-regulatory cell dysfunction and altered B-cell responses contribute to loss of immune tolerance.

• Bacterial translocation and dysbiosis hypothesis: The strong association between PSC and IBD suggests that abnormal intestinal permeability and dysbiosis may permit bacterial lipopolysaccharide (LPS) and other microbial antigens to enter portal circulation. These pathogen-associated molecular patterns (PAMPs) can activate toll-like receptors (TLRs) on biliary epithelial cells, hepatic stellate cells, and Kupffer cells, triggering inflammatory cascades. Specific bacterial taxa (reduced Faecalibacterium prausnitzii, altered Firmicutes/Bacteroidetes ratio) correlate with disease severity. Increased intestinal translocation of bacterial DNA has been demonstrated in PSC patients, supporting this hypothesis. This mechanism explains why PSC is rare without concurrent IBD and why colectomy may halt disease progression in some patients.

• Biliary epithelial cell dysfunction and duct injury: Chronic inflammation damages the biliary epithelial cells (cholangiocytes), disrupting tight junctions and impairing immune regulation at the biliary mucosa. Cholangiocytes express enhanced levels of adhesion molecules (ICAM-1, ELAM-1) and produce chemokines (CCL2, CXCL10), perpetuating lymphocyte recruitment. Repeated ischemic injury to bile ducts, potentially from microvascular inflammation and vanishing bile duct syndrome, contributes to progressive stricturing. The epithelial-mesenchymal transition (EMT) of cholangiocytes promotes their transdifferentiation into fibroblasts, directly contributing to periductal fibrosis. Dysregulated cholangiocyte apoptosis and aberrant expression of fibrogenic cytokines (IL-17, TNF-α, TGF-β) activate hepatic stellate cells, driving myofibroblast differentiation and excessive collagen deposition around bile ducts.

• Oxidative stress and toxic metabolite accumulation: Mitochondrial dysfunction within cholangiocytes leads to enhanced oxidative stress, generating reactive oxygen species (ROS) that damage cellular DNA and proteins. This may be exacerbated by abnormal lipid peroxidation and impaired antioxidant defenses. Retained bile acids accumulate within cholangiocytes and hepatocytes, activating farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (TGR5) signaling in dysregulated fashion, leading to altered cell survival and inflammatory signaling. The accumulation of 7-ketocholestanol and other potentially toxic cholestatic metabolites may directly injure the biliary epithelium.

• Progressive fibrosis to cirrhosis: Once periductal fibrosis is established, aberrant wound-healing responses lock in inflammation. Hepatic stellate cells, activated by chronic inflammation and cytokine signals (particularly TGF-β and PDGF), undergo myofibroblast transition and deposit excessive extracellular matrix rich in types I and III collagen. This process extends beyond the portal triads to produce "onion-skin" fibrosis characteristic of PSC. Progressive bridging fibrosis and eventually cirrhotic transformation with nodule formation follows. The natural history typically spans 10–15 years from diagnosis to cirrhosis in untreated patients, though considerable individual variation exists.

• Inflammatory bowel disease (strongest association): PSC occurs in 2.4–7.5% of ulcerative colitis patients and in 0.5–1.5% of Crohn's disease patients. Notably, PSC can develop or persist after colectomy in up to 50% of patients, indicating that PSC is not simply a direct consequence of IBD but rather represents a parallel manifestation of shared genetic/immune susceptibility. Patients with UC and PSC have more extensive colonic disease and increased colorectal cancer risk. Conversely, not all PSC patients have clinically evident IBD; however, colonoscopy with random biopsies reveals subclinical inflammation in 60–75% of "PSC without IBD" cases, supporting the hypothesis that IBD is virtually universal in PSC but sometimes subclinical.

• Genetic susceptibility: Strong association with HLA-B8 and HLA-DR3 haplotypes (particularly in Northern European populations) indicates inherited predisposition. Genome-wide association studies (GWAS) have identified additional susceptibility loci including FAP (familial adenomatous polyposis gene region), CARD9, and others involved in immune regulation. These genetic factors alone are insufficient for disease development, as evidenced by incomplete penetrance and the requirement for environmental triggers.

• Infectious agents and molecular mimicry: Serological evidence implicates various bacteria (Helminths, Pseudomonas aeruginosa, Mycobacterium avium paratuberculosis), though causality remains unproven. The hypothesis that bacterial antigens cross-react with biliary epithelial antigens through molecular mimicry is supported by the presence of autoantibodies and T-cell responses targeting both bacterial and self-antigens. Viral infections (CMV, EBV, hepatitis viruses) may also trigger disease in susceptible hosts.

• Secondary sclerosing cholangitis causes (must be excluded): These include immunoglobulin G4 (IgG4)-associated cholangitis, primary biliary cholangitis (PBC) with overlap features, recurrent/secondary infection (parasitic infections in endemic areas, retrograde cholangitis from stones or sphincter of Oddi dysfunction), ischemic cholangitis (after surgical injury, liver transplantation, or vasculitis), and cholangitis associated with cystic fibrosis, Caroli disease, or biliary atresia. IgG4-related disease presenting as sclerosing cholangitis is increasingly recognized and must be distinguished from PSC because it may respond to corticosteroids and has a different prognosis.

• Asymptomatic disease with abnormal liver chemistry: Approximately 25–50% of PSC patients are discovered incidentally through screening (e.g., routine laboratory testing, imaging for other reasons, or as part of IBD evaluation). These patients have elevated serum alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) without jaundice or pruritus. The long asymptomatic phase allows time for intervention before irreversible cirrhosis develops.

• Fatigue: Persistent, progressive fatigue is one of the earliest and most common symptoms, affecting 70% of symptomatic patients. The mechanism is multifactorial: altered bile acid metabolism and their neurotoxic effects, impaired hepatic synthetic function, dysregulated serotonin metabolism, and chronic inflammation all contribute. Fatigue may precede biochemical evidence of cirrhosis by years and significantly impacts quality of life.

• Pruritus (cholestasis-induced itching): Affects 20–50% of symptomatic patients. The sensation arises from accumulation of bile salts and other cholestatic autacoids (lysophosphatidic acid, opioid agonists) in the skin and activation of sensory C-fiber neurons. Pruritus in PSC tends to be worse in the evening and may disrupt sleep. Unlike in PBC, pruritus is often less severe and may respond less predictably to treatment. Pruritus often indicates worsening cholestasis and biliary obstruction.

• Jaundice: Develops when obstructing bile duct strictures cause significant cholestasis, typically in mid-to-advanced disease. Frank icterus reflects elevated serum conjugated bilirubin (>2–3 mg/dL). Jaundice may develop acutely if strictures worsen or a superimposed infection occurs, or gradually as progressive fibrosis narrows ducts.

• Abdominal pain: Upper abdominal or right upper quadrant pain occurs in 10–20% of patients and reflects biliary colic from strictures, acute cholangitis, or associated cholecystitis. Pain may be colicky (suggesting stones) or dull and persistent (suggesting inflammation). Acute severe pain with fever suggests acute cholangitis, a medical emergency.

• Recurrent cholangitis: Strictured, dilated bile ducts create a stagnant milieu favoring bacterial proliferation and infection. Acute cholangitis presents with the classic triad of fever, jaundice, and right upper quadrant pain (Reynolds' pentad adds altered mental status and hypotension indicating septic shock). This complication becomes increasingly common as disease progresses and may accelerate functional deterioration.

• Portal hypertension and decompensation (late disease): As PSC progresses to cirrhosis, portal hypertension develops. Patients develop ascites, variceal bleeding, encephalopathy, and hepatic synthetic dysfunction (coagulopathy, hypoalbuminemia). These represent advanced disease and mark the transition to end-stage liver disease necessitating transplantation.

• Physical examination findings: Early disease may show only hepatosplenomegaly on examination. Stigmata of chronic liver disease appear with progression: jaundice, spider angiomas, palmar erythema, gynecomastia (from altered estrogen metabolism), caput medusae, splenomegaly (from portal hypertension), and ascites. Temporal wasting and muscle atrophy reflect malnutrition from hepatic dysfunction. Asterixis (flapping tremor) indicates hepatic encephalopathy.

• PSC with autoimmune hepatitis (PSC-AIH overlap): 6–17% of PSC patients develop features of autoimmune hepatitis with prominent elevation of transaminases (often >2–3 times upper limit normal), hypergammaglobulinemia, and autoimmune serologies. These patients may show more aggressive disease progression and require treatment with immunosuppressive agents.

• Liver biochemistry pattern: The hallmark is cholestatic pattern with elevated alkaline phosphatase (often 2–4 times upper limit normal, range 100–400 IU/L) and elevated gamma-glutamyl transferase (GGT), reflecting impaired hepatic excretion from biliary obstruction. Elevated serum bilirubin occurs in a minority (25–50%) at presentation and indicates more advanced obstruction or cirrhosis; direct (conjugated) hyperbilirubinemia predominates. Transaminases (ALT, AST) are variably elevated but typically less than 2 times normal (in contrast to autoimmune hepatitis or viral hepatitis); marked elevation suggests overlap with autoimmune hepatitis. Albumin and prothrombin time (PT/INR) remain normal until cirrhosis develops. In advanced cirrhosis, albumin falls and PT/INR prolongs, indicating synthetic dysfunction.

• Autoimmune and serologic markers: PSC-specific serology is limited. Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) are positive in 40–80% of PSC patients but lack sensitivity and specificity (also seen in IBD, microscopic colitis, drug-induced liver injury). Antinuclear antibody (ANA) and anti-smooth muscle antibody (ASMA) are positive in 10–50% and 10–30% of patients respectively but are non-specific. Anti-mitochondrial antibodies (AMA), characteristic of primary biliary cholangitis, should be negative in PSC; their presence suggests overlap with PBC or misdiagnosis. Immunoglobulin levels may be elevated, reflecting chronic immune activation; markedly elevated IgG (especially IgG4 >135 mg/dL or >40% of total IgG) should prompt evaluation for IgG4-associated cholangitis.

• Magnetic resonance cholangiopancreatography (MRCP) as primary diagnostic imaging: MRCP is the gold-standard imaging modality for PSC diagnosis, offering superior sensitivity (>95%) and specificity (>95%) compared to endoscopic retrograde cholangiopancreatography (ERCP) while avoiding procedural risks (pancreatitis, infection). MRCP demonstrates the characteristic findings: diffuse multifocal strictures and segmental dilation of intrahepatic and/or extrahepatic bile ducts, creating a "beads-on-a-string" appearance. The strictures are typically short (<1 cm) and concentric. MRCP also evaluates for a dominant stricture (defined as stenosis of the common bile duct <1.5 mm diameter or common hepatic duct <1.5 mm, or any stricture with upstream dilation within 5 cm), which identifies patients at risk for cholangiocarcinoma and those who may benefit from endoscopic therapy. PSC variants include PSC with small-duct disease (5–15% of cases), where cholangiographic appearance is normal or nearly normal despite abnormal liver chemistry and liver biopsy findings of PSC, and PSC with dominant stricture, where a single stenosis of the common bile duct (or common hepatic duct) predominates, mimicking benign obstruction or requiring differentiation from malignancy.

• Liver biopsy findings: Although not required for diagnosis when cholangiography is conclusive, liver biopsy helps assess disease stage and exclude overlap with autoimmune hepatitis. Characteristic histology includes periductal fibrosis ("onion-skin" pattern of concentric rings of fibrous tissue around bile ducts), bile duct proliferation (reflecting obstruction), cholestasis, and portal inflammation. In early disease, inflammation may be relatively mild with prominent fibrosis. Advanced stages show bridging fibrosis and cirrhosis. The presence of lymphoid aggregates or significant portal-based inflammation suggests possible autoimmune hepatitis overlap. Interface hepatitis with plasma cell infiltration indicates autoimmune features. Ductular reaction (proliferation of small bile ducts at the interface between parenchyma and fibrosis) is prominent.

• Diagnostic criteria and scoring systems: PSC diagnosis is established when: (1) cholestasis pattern on liver chemistry (elevated ALP ± elevated bilirubin), (2) characteristic cholangiographic findings on MRCP (stricturing and dilation of bile ducts), and (3) exclusion of secondary causes of sclerosing cholangitis. The Mayo PSC Prognostic Model incorpor

Immediate stabilisation

• Acute bacterial cholangitis is the emergency. Stagnant bile above strictures permits enteric bacterial overgrowth and ascending infection. Treat with fluid resuscitation, blood cultures, broad-spectrum IV antibiotics covering gram-negatives and anaerobes (e.g., piperacillin-tazobactam), and biliary drainage by ERCP, urgently if there is shock or altered mentation (Reynolds pentad), per Tokyo Guidelines/IDSA-style intra-abdominal infection principles.

Symptom-directed first-line therapy

• Bile acid sequestrants (cholestyramine): first-line for pruritus; binds pruritogens in the gut lumen and interrupts enterohepatic recycling. Dose it apart from other drugs and fat-soluble vitamins to avoid binding them.
• Second-line antipruritics: rifampin (PXR-mediated pruritogen metabolism), then an opioid antagonist (naltrexone), then sertraline — the AASLD stepwise sequence.
• Fat-soluble vitamin (A, D, E, K) repletion for cholestatic malabsorption, plus bone densitometry, calcium and vitamin D for cholestatic osteoporosis.

Stricture management

• ERCP with balloon dilation for a symptomatic dominant stricture (jaundice, pruritus, cholangitis). Always obtain brush cytology ± FISH to exclude cholangiocarcinoma. AASLD favors dilation alone over routine stenting; short-term stents are reserved for dilation failure. Peri-procedural antibiotics are given because instrumented obstructed ducts readily seed infection.

Definitive therapy

• Liver transplantation is the only intervention that prolongs survival, indicated for decompensated cirrhosis, intractable pruritus, or recurrent bacterial cholangitis (MELD exception points may apply). Perihilar cholangiocarcinoma is transplantable only within strict protocolized neoadjuvant criteria.

Avoid

• High-dose ursodeoxycholic acid (~28–30 mg/kg/day): associated with worse outcomes; AASLD recommends against it. Low/standard-dose UDCA improves ALP but has no proven survival benefit and is not routinely recommended.
• Corticosteroids/immunosuppressants: ineffective in classic PSC; reserve for IgG4-related sclerosing cholangitis or AIH-overlap.

Emergencies

• Acute bacterial (ascending) cholangitis: bile stasis behind strictures permits enteric bacterial colonization; signals itself as Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad with hypotension and confusion. Requires antibiotics plus urgent biliary drainage.
• Variceal hemorrhage and other decompensation: portal hypertension from biliary cirrhosis; signalled by hematemesis, ascites, or encephalopathy. Note that portal hypertension in PSC can be presinusoidal and precede true cirrhosis.

Malignant complications (the exam favorites)

• Cholangiocarcinoma: chronic cholangiocyte inflammation drives dysplasia–carcinoma sequence; lifetime risk is substantial and risk is highest in the first year after PSC diagnosis. Signalled by rapid clinical deterioration, new or progressive jaundice, weight loss, a rising CA 19-9, or a new/enlarging dominant stricture. AASLD supports imaging (MRCP or ultrasound) ± CA 19-9 surveillance at 6–12 month intervals in adults.
• Gallbladder carcinoma: gallbladder polyps in PSC carry high malignant potential; cholecystectomy is advised for polyps meeting size criteria on surveillance ultrasound.
• Colorectal cancer in PSC-IBD: risk is higher than in IBD alone with a right-sided/proximal predominance; guidance (AASLD, and IBD surveillance guidance from ACG/AGA) is colonoscopy at PSC diagnosis and then annual surveillance if IBD is present.
• Hepatocellular carcinoma: only once cirrhosis is established — then standard 6-monthly ultrasound surveillance applies.

Cholestasis-related complications

• Fat-soluble vitamin deficiency: night blindness (A), osteomalacia (D), neuropathy (E), prolonged INR correcting with vitamin K.
• Metabolic bone disease: cholestatic osteoporosis; fragility fracture or low DEXA T-score.
• Pigment stones and choledocholithiasis, worsening obstruction and cholangitis risk.

Treatment-related

• Post-ERCP pancreatitis and iatrogenic cholangitis: the main reason MRCP, not ERCP, is the diagnostic test.
• High-dose UDCA: associated with worse clinical outcomes.
• Recurrent PSC in the allograft after transplantation, plus chronic immunosuppression risks; IBD activity and colorectal cancer risk may increase post-transplant.

• The image buzzword: multifocal short strictures alternating with dilations — "beads on a string" on MRCP. The histologic buzzword is onion-skin concentric periductal fibrosis.
• Single best next step: in a young-to-middle-aged man with ulcerative colitis and an isolated cholestatic alkaline phosphatase elevation, order MRCP, not ERCP. ERCP is therapeutic (dilation, brushings) and carries post-ERCP pancreatitis risk; it is not the initial diagnostic study.
• The association examiners test: ulcerative colitis. Remember the directionality — most PSC patients have IBD, but only a small minority of UC patients get PSC. Colectomy does not reliably cure PSC.
• PSC vs PBC distractor: PSC = male, AMA-negative, p-ANCA often positive, large ducts, MRCP beading. PBC = middle-aged woman, AMA-positive, intrahepatic small ducts, florid duct lesion granulomas. Choosing "AMA" in a PSC stem is the classic trap; if AMA is positive, rethink the diagnosis or overlap.
• The therapy trap: high-dose ursodeoxycholic acid is not protective and is associated with harm (AASLD recommends against it). Corticosteroids do nothing for classic PSC — they belong to IgG4-related sclerosing cholangitis, which is the steroid-responsive mimic to check for with a serum IgG4 level.
• Sudden deterioration = cancer until proven otherwise: new jaundice, weight loss, and a rising CA 19-9 in known PSC → cholangiocarcinoma; get imaging plus ERCP brushings with FISH. Risk is front-loaded in the first year after diagnosis.
• Colonoscopy is part of the PSC workup: perform it at diagnosis even without GI symptoms (subclinical colitis is common), then annual surveillance if IBD is found — PSC-IBD colorectal cancer is disproportionately right-sided.
• Definitive therapy is transplantation; no drug improves transplant-free survival. Also remember cholestatic sequelae worth points: fat-soluble vitamin deficiency and osteoporosis.